Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of LY-03005 in major depressive disorder (MDD)

Trial Profile

A phase 3 study of LY-03005 in major depressive disorder (MDD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2018

At a glance

  • Drugs LY 03005 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jul 2018 Status changed from planning to recruiting, according to a Luye Pharma media release.
    • 12 Jun 2018 New trial record
    • 06 Jun 2018 According to a Luye Pharma media release, the company expects to begin the trial this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top